NCT02527746 2024-02-23
Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
EVIVE Biotechnology
Phase 1 Completed
EVIVE Biotechnology
AstraZeneca
Teva Branded Pharmaceutical Products R&D, Inc.
GBG Forschungs GmbH
GBG Forschungs GmbH
Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd